DELIVER: Extending the benefits of SGLT-2 inhibitors

Authors

  • Kerollos Samaan Cardiology Department, Cairo University, Cairo, Egypt
  • Kerolos Wagdy Cardiology Department, Aswan Heart Centre, Aswan, Egypt

DOI:

https://doi.org/10.21542/gcsp.2023.21

Abstract

The DELIVER trial investigated the efficacy and safety of dapagliflozin in patients with heart failure and preserved or mildly reduced ejection fraction. The trial demonstrated that dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death compared to placebo. The benefit was mainly driven by a decrease in heart failure hospitalizations, with no significant impact on mortality. Patients with different ejection fractions and diabetes status showed similar treatment effects. Dapagliflozin also improved functional capacity and quality of life. These findings support the use of SGLT-2 inhibitors in HFpEF and HFmrEF, potentially influencing clinical practice and future guidelines.

Downloads

Published

2023-06-27

Issue

Vol. 2023 No. 3 (2023)

Section

Lessons from the trials

License

Copyright (c) 2023 Kerollos Samaan, Kerolos Wagdy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.